Duchenne Muscular Dystrophy (DMD) is a rare genetic condition that affects approximately 1 in 5,000 boys worldwide. It is caused by a mutation in the dystrophin gene and leads to progressive muscle weakness and wasting. Typically, symptoms of DMD begin to appear in children between the ages of 3 to 5 years, and by early adolescence, most patients require a wheelchair. DMD also affects the heart and respiratory muscles, which can result in early death (most do not live beyond twenties). Individuals with DMD can also have developmental delays and behavioral challenges.

DMD is 100% fatal, there is no cure for DMD now. Very few therapies for some type of mutations are currently available to slow the progression of DMD. However, ongoing research and progress in treatment options provide hope for DMD patients and their families. Increased awareness and funding will expedite progress toward better treatments and a cure for this devastating disease.

Families dealing with DMD face substantial additional expenses, including medical bills, travel expenses for medical visits and trials, home modifications, and special education. According to the Muscular Dystrophy Association, these costs can accumulate to $50,000 or more per year.